267 related articles for article (PubMed ID: 35142777)
1. Vasculature-on-a-chip platform with innate immunity enables identification of angiopoietin-1 derived peptide as a therapeutic for SARS-CoV-2 induced inflammation.
Lu RXZ; Lai BFL; Rafatian N; Gustafson D; Campbell SB; Banerjee A; Kozak R; Mossman K; Mubareka S; Howe KL; Fish JE; Radisic M
Lab Chip; 2022 Mar; 22(6):1171-1186. PubMed ID: 35142777
[TBL] [Abstract][Full Text] [Related]
2. The SARS-CoV-2 spike protein alters barrier function in 2D static and 3D microfluidic in-vitro models of the human blood-brain barrier.
Buzhdygan TP; DeOre BJ; Baldwin-Leclair A; Bullock TA; McGary HM; Khan JA; Razmpour R; Hale JF; Galie PA; Potula R; Andrews AM; Ramirez SH
Neurobiol Dis; 2020 Dec; 146():105131. PubMed ID: 33053430
[TBL] [Abstract][Full Text] [Related]
3. Mast cells activated by SARS-CoV-2 release histamine which increases IL-1 levels causing cytokine storm and inflammatory reaction in COVID-19.
Conti P; Caraffa A; Tetè G; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Di Emidio P; Ronconi G
J Biol Regul Homeost Agents; 2020 Sep-Oct,; 34(5):1629-1632. PubMed ID: 32945158
[TBL] [Abstract][Full Text] [Related]
4. CCR2 Signaling Restricts SARS-CoV-2 Infection.
Vanderheiden A; Thomas J; Soung AL; Davis-Gardner ME; Floyd K; Jin F; Cowan DA; Pellegrini K; Shi PY; Grakoui A; Klein RS; Bosinger SE; Kohlmeier JE; Menachery VD; Suthar MS
mBio; 2021 Dec; 12(6):e0274921. PubMed ID: 34749524
[TBL] [Abstract][Full Text] [Related]
5. Endothelial dysfunction in COVID-19: a position paper of the ESC Working Group for Atherosclerosis and Vascular Biology, and the ESC Council of Basic Cardiovascular Science.
Evans PC; Rainger GE; Mason JC; Guzik TJ; Osto E; Stamataki Z; Neil D; Hoefer IE; Fragiadaki M; Waltenberger J; Weber C; Bochaton-Piallat ML; Bäck M
Cardiovasc Res; 2020 Dec; 116(14):2177-2184. PubMed ID: 32750108
[TBL] [Abstract][Full Text] [Related]
6. Elevated Cytokine Levels in Plasma of Patients with SARS-CoV-2 Do Not Contribute to Pulmonary Microvascular Endothelial Permeability.
Kovacs-Kasa A; Zaied AA; Leanhart S; Koseoglu M; Sridhar S; Lucas R; Fulton DJ; Vazquez JA; Annex BH
Microbiol Spectr; 2022 Feb; 10(1):e0167121. PubMed ID: 35171047
[TBL] [Abstract][Full Text] [Related]
7. Monocyte-crosstalk drives interferon-mediated signaling following SARS-CoV-2 exposure.
Theobald SJ; Rybniker J
Mol Syst Biol; 2022 Sep; 18(9):e11256. PubMed ID: 36094010
[TBL] [Abstract][Full Text] [Related]
8. Direct Activation of Endothelial Cells by SARS-CoV-2 Nucleocapsid Protein Is Blocked by Simvastatin.
Qian Y; Lei T; Patel PS; Lee CH; Monaghan-Nichols P; Xin HB; Qiu J; Fu M
J Virol; 2021 Nov; 95(23):e0139621. PubMed ID: 34549987
[TBL] [Abstract][Full Text] [Related]
9. Novel evidence of Thymosin α1 immunomodulatory properties in SARS-CoV-2 infection: Effect on innate inflammatory response in a peripheral blood mononuclear cell-based in vitro model.
Ricci D; Etna MP; Severa M; Fiore S; Rizzo F; Iannetta M; Andreoni M; Balducci S; Stefanelli P; Palamara AT; Coccia EM
Int Immunopharmacol; 2023 Apr; 117():109996. PubMed ID: 36933449
[TBL] [Abstract][Full Text] [Related]
10. A Novel Glucocorticoid and Androgen Receptor Modulator Reduces Viral Entry and Innate Immune Inflammatory Responses in the Syrian Hamster Model of SARS-CoV-2 Infection.
Rocha SM; Fagre AC; Latham AS; Cummings JE; Aboellail TA; Reigan P; Aldaz DA; McDermott CP; Popichak KA; Kading RC; Schountz T; Theise ND; Slayden RA; Tjalkens RB
Front Immunol; 2022; 13():811430. PubMed ID: 35250984
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibody therapy in COVID-19.
Conti P; Pregliasco FE; Calvisi V; Caraffa Al; Gallenga CE; Kritas SK; Ronconi G
J Biol Regul Homeost Agents; 2021; 35(2):423-427. PubMed ID: 33904269
[TBL] [Abstract][Full Text] [Related]
12. IL-1 induces throboxane-A2 (TxA2) in COVID-19 causing inflammation and micro-thrombi: inhibitory effect of the IL-1 receptor antagonist (IL-1Ra).
Conti P; Caraffa A; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Di Emidio P; Ronconi G; Toniato E
J Biol Regul Homeost Agents; 2020 Sep-Oct,; 34(5):1623-1627. PubMed ID: 32744052
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 Spike Protein Induces Paracrine Senescence and Leukocyte Adhesion in Endothelial Cells.
Meyer K; Patra T; Vijayamahantesh ; Ray R
J Virol; 2021 Aug; 95(17):e0079421. PubMed ID: 34160250
[TBL] [Abstract][Full Text] [Related]
14. Coronavirus-19 (SARS-CoV-2) induces acute severe lung inflammation via IL-1 causing cytokine storm in COVID-19: a promising inhibitory strategy.
Conti P; Caraffa A; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Ronconi G
J Biol Regul Homeost Agents; 2020; 34(6):1971-1975. PubMed ID: 33016027
[TBL] [Abstract][Full Text] [Related]
15. Recombinant ACE2 Expression Is Required for SARS-CoV-2 To Infect Primary Human Endothelial Cells and Induce Inflammatory and Procoagulative Responses.
Nascimento Conde J; Schutt WR; Gorbunova EE; Mackow ER
mBio; 2020 Dec; 11(6):. PubMed ID: 33310781
[TBL] [Abstract][Full Text] [Related]
16. Induction of Exaggerated Cytokine Production in Human Peripheral Blood Mononuclear Cells by a Recombinant SARS-CoV-2 Spike Glycoprotein S1 and Its Inhibition by Dexamethasone.
Olajide OA; Iwuanyanwu VU; Lepiarz-Raba I; Al-Hindawi AA
Inflammation; 2021 Oct; 44(5):1865-1877. PubMed ID: 33860869
[TBL] [Abstract][Full Text] [Related]
17. SARS-CoV-2 disrupts respiratory vascular barriers by suppressing Claudin-5 expression.
Hashimoto R; Takahashi J; Shirakura K; Funatsu R; Kosugi K; Deguchi S; Yamamoto M; Tsunoda Y; Morita M; Muraoka K; Tanaka M; Kanbara T; Tanaka S; Tamiya S; Tokunoh N; Kawai A; Ikawa M; Ono C; Tachibana K; Kondoh M; Obana M; Matsuura Y; Ohsumi A; Noda T; Yamamoto T; Yoshioka Y; Torisawa YS; Date H; Fujio Y; Nagao M; Takayama K; Okada Y
Sci Adv; 2022 Sep; 8(38):eabo6783. PubMed ID: 36129989
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 productively infects primary human immune system cells in vitro and in COVID-19 patients.
Pontelli MC; Castro ÍA; Martins RB; La Serra L; Veras FP; Nascimento DC; Silva CM; Cardoso RS; Rosales R; Gomes R; Lima TM; Souza JP; Vitti BC; Caetité DB; de Lima MHF; Stumpf SD; Thompson CE; Bloyet LM; Toller-Kawahisa JE; Giannini MC; Bonjorno LP; Lopes MIF; Batah SS; Siyuan L; Luppino-Assad R; Almeida SCL; Oliveira FR; Benatti MN; Pontes LLF; Santana RC; Vilar FC; Auxiliadora-Martins M; Shi PY; Cunha TM; Calado RT; Alves-Filho JC; Zamboni DS; Fabro AT; Louzada-Junior P; Oliveira RDR; Whelan SPJ; Cunha FQ; Arruda E
J Mol Cell Biol; 2022 Aug; 14(4):. PubMed ID: 35451490
[TBL] [Abstract][Full Text] [Related]
19. SARS-CoV-2 causes severe epithelial inflammation and barrier dysfunction.
Deinhardt-Emmer S; Böttcher S; Häring C; Giebeler L; Henke A; Zell R; Jungwirth J; Jordan PM; Werz O; Hornung F; Brandt C; Marquet M; Mosig AS; Pletz MW; Schacke M; Rödel J; Heller R; Nietzsche S; Löffler B; Ehrhardt C
J Virol; 2021 Apr; 95(10):. PubMed ID: 33637603
[TBL] [Abstract][Full Text] [Related]
20. Targeting Doublecortin-Like Kinase 1 (DCLK1)-Regulated SARS-CoV-2 Pathogenesis in COVID-19.
Undi RB; Larabee JL; Filiberti A; Ulahannan S; Aravindan S; Stroberg E; Barton LM; Duval EJ; Mukhopadhyay S; Henthorn JC; Akins D; Houchen CW; Huycke MM; Ali N
J Virol; 2022 Sep; 96(17):e0096722. PubMed ID: 35943255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
